Judges will employ the following definition of "novel" and "innovative research":

• Uses new paradigms to approach clinical problems.

• Develops techniques or assays to new targets.

• Adapts existing methods or models developed in other disciplines to solve clinical problems in HIV/AIDS.

The research proposals will be considered according to: potential importance to the field and health in general; originality; appropriateness of the methodology and scope of the project; and the researchers' ability to conduct the proposed research.

Research projects submitted for the award likely will be in the early stage, and not yet sufficiently developed for a major research grant, but if successful, may qualify for major funding in future years.

Award recipients will be announced in September 2002 at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Diego. The awards will be paid Nov. 1, 2002.

"While amazing advances have been made in recent years, and men and women with the terrible disease are living fuller, longer lives, there is much to be done," said Barney Koszalka, Ph.D., director of the virology division for GSK. "We initiated the Drug Discovery and Development Award program in 2001, and last year's recipients included researchers who focused on various approaches to inhibiting HIV's ability to integrate into human cells. They continue their good work, but there are an infinite number of other potential approaches and we want to support the efforts, with no strings attached."

Recipients of the 2001 Drug Discovery and Development Award were Richard Kornbluth, M.D. Ph.D, University of Califo
'"/>